



Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences

August 3, 2020

DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform today announced it will report financial results for the second quarter of 2020 on August 13, 2020.

Matt Kane, Chief Executive Officer and co-founder of Precision along with Chris Heery, Chief Medical Officer at Precision, will also participate in the following upcoming investor conferences:

William Blair Biotech Focus Conference

Date: August 6, 2020

Fireside chat: 12:00 to 12:45 PM EDT

BTIG Virtual Biotechnology Conference

Date: August 10, 2020

Fireside chat: 10:30 – 10:55 AM EDT

Live webcasts of each presentation will be accessible on the Company's website, www.PrecisionBiosciences.com, under the Investors & Media section.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.messier@precisionbiosciences.com

Josh Rappaport

Stern Investor Relations

josh.rappaport@sternir.com